Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (1215)	5/13/1998 3:38:00 PM
From: muddphudd	Read Replies (2) \| Respond to of 1359

Looks like Roche got the green light for Zenecal, their anti-obesity drug. It is a great drug. I worked in a clinic that was part of the clinical trials for this baby. Zenecal inhibits gastric lipase. It blocks the breakdown of fats in our digestive track so that we can not absorb them. It lacks all the side-effects of other anorectic drugs because it does not work on serotonin levels or other brain chemistries. In fact, it really doesn't work in the body. It is not appreciably absorbed by the GI tract. It only works there. The side-effects are fatty stools. This resolves in 1-2 months. This may prove to be a major competitor to the current anorectic drugs available, even to Redux.